<DOC>
	<DOCNO>NCT02786927</DOCNO>
	<brief_summary>This Phase IV multi-center , randomize , open-label , cross-over , placebo study subject Chronic Obstructive Pulmonary Disease ( COPD ) compare inhaler-specific preference attribute two inhaler - ELLIPTA dry powder inhaler ( DPI ) HANDIHALER DPI . The primary objective study evaluate whether subject COPD prefer ELLIPTA inhaler HANDIHALER DPI base number step need take medication . All subject use ELLIPTA inhaler HANDIHALER inhaler correspond treatment period base randomisation scheme , end 2 period , complete inhaler preference questionnaire . Subjects self-administer inhalation daily 5-9 day treatment period . This study placebo-only , neither inhaler contain active treatment . Subjects continue current COPD medication ( ) prescribe , follow regular physician COPD healthcare study . Approximately 211 subject enrol study . ELLIPTA trademark GlaxoSmithKline group company . HANDIHALER trademark Boehringer Ingelheim International GmbH .</brief_summary>
	<brief_title>Preference Attributes ELLIPTA Dry Powder Inhaler ( DPI ) HANDIHALER DPI Subjects With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>&gt; =40 year age Visit 1 . Diagnosis COPD document history COPD least 6 month . Severity Disease : Post albuterol/salbutamol force expiratory volume one second ( FEV1 ) /forced vital capacity ( FVC ) ratio &lt; 0.70 FEV1 &lt; =70 % predict obtain within two year Visit 1 . Smoking History : Current former ( defined subject quit smoke least 3 month prior Screening/Visit 1 ) cigarette smoker &gt; 10 packyear smoke history . Number pack year = ( number cigarette per day/20 ) x number year smoke ( example , 10 packyears equal 20 cigarette per day 10 year , 10 cigarette per day 20 year ) . Current COPD Therapy : 1 . Currently receive maintenance therapy one longacting bronchodilator , longacting muscarinic antagonist ( LAMA ; also know longacting anticholinergic ) , longacting beta 2agonist ( LABA ) , inhale corticosteroid ( ICS ) /LABA combination treatment COPD . Subjects must able continue use currently prescribe COPD maintenance inhaler therapy throughout study need short act betaadrenergic agonist ( SABA ) short act muscarinic antagonist ( SAMA ) rescue use . 2 . Has current maintenance COPD treatment least 4 week prior Screening/Visit 1 evaluate unlikely change COPD treatment within 4 week Visit 1 . Males Females pregnant plan pregnancy study lactate . Capable give sign informed consent , include compliance requirement restriction define study . Subject understand willing , able , likely comply study procedure restriction . Subject must able read , comprehend , record information English . Asthma : Subjects current diagnosis asthma . Subjects prior history asthma eligible current diagnosis COPD . Recent experience ELLIPTA inhaler : Subjects use ELLIPTA inhaler within 6 month ( 180 day ) prior Visit 1 . Recent experience HANDIHALER inhaler : Subjects use HANDIHALER inhaler within 6 month ( 180 day ) prior Visit 1 . Poorly control COPD : Subjects symptoms poorly control COPD : 1 . Acute worsen COPD manage subject corticosteroid antibiotic require treatment prescribed physician , 4 week prior Visit 1 . 2 . Hospitalization due acute worsen COPD within 4 week Visit 1 . 3 . Use total 8 puffs/day shortacting symptom relief medication albuterol ipratropium 2 consecutive day 3 day within 7 day immediately precede Visit 1 . 4 . Changes COPD symptom sign , suggest worsen COPD health status Visit 1 . Other Disease Abnormalities : 1 . Subjects suspect evidence oropharyngeal candidiasis . 2 . Historical current evidence clinically significant rapidly progress unstable cardiovascular , neurological , renal , hepatic , immunological , endocrine ( include uncontrolled diabetes thyroid disease ) haematological abnormality uncontrolled . Significant define disease , opinion investigator , would put safety subject risk participation , would affect analysis disease/condition exacerbate study . 3 . Subjects history psychiatric disease , intellectual deficiency , poor motivation condition limit validity inform consent participate study . Compliance : Subjects risk noncompliance , unable comply study procedure , unable continue current COPD medication . Drug/alcohol abuse : Subjects know suspected alcohol drug abuse Visit 1 opinion investigator could interfere subject 's proper completion protocol requirement . Drug/Food Allergy : A history hypersensitivity component study inhaler ( example , lactose , magnesium stearate ) . In addition , subject history severe milk protein allergy , opinion study physician , contraindicate participation also exclude . Investigational Product : Subjects receive investigational drug and/or medical device within 30 day entry study ( Screening/Visit 1 ) , within five drug halflives investigational drug , whichever longer . Affiliation Investigator 's Site : A subject eligible study he/she immediate family member participate investigator , subinvestigator , study coordinator , employee participate investigator .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HANDIHALER</keyword>
	<keyword>Dry Powder Inhaler</keyword>
	<keyword>COPD</keyword>
	<keyword>ELLIPTA</keyword>
	<keyword>Inhaler preference attribute</keyword>
</DOC>